{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699994302631168.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1093/eurheartj/ehw110"}},{"identifier":{"@type":"URI","@value":"http://academic.oup.com/eurheartj/article-pdf/37/42/3192/13244850/ehw110.pdf"}}],"dc:title":[{"@value":"Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699994302631168","@type":"Researcher","foaf:name":[{"@value":"Nikolaus Marx"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699994302631169","@type":"Researcher","foaf:name":[{"@value":"Darren K. McGuire"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"0195668X"},{"@type":"EISSN","@value":"15229645"}],"prism:publicationName":[{"@value":"European Heart Journal"}],"dc:publisher":[{"@value":"Oxford University Press (OUP)"}],"prism:publicationDate":"2016-05-05","prism:volume":"37","prism:number":"42","prism:startingPage":"3192","prism:endingPage":"3200"},"reviewed":"false","url":[{"@id":"http://academic.oup.com/eurheartj/article-pdf/37/42/3192/13244850/ehw110.pdf"}],"createdAt":"2016-11-17","modifiedAt":"2024-06-20","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050588976822001920","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Rationale and design of a multicenter placebo-controlled double-blind randomized trial to evaluate the effect of empagliflozin on endothelial function: the EMBLEM trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1360298757204601472","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Cardiorenal Syndrome: The Role of Neural Connections Between the Heart and the Kidneys"}]},{"@id":"https://cir.nii.ac.jp/crid/1360576118839588224","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Enhanced Expression and Function of Renal SGLT2 (Sodium-Glucose Cotransporter 2) in Heart Failure: Role of Renal Nerves"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1093/eurheartj/ehw110"},{"@type":"CROSSREF","@value":"10.1161/circresaha.122.319989_references_DOI_Sr5FmHPrDELw1k8WALkuKcB8xH1"},{"@type":"CROSSREF","@value":"10.1186/s12933-017-0532-8_references_DOI_Sr5FmHPrDELw1k8WALkuKcB8xH1"},{"@type":"CROSSREF","@value":"10.1161/circheartfailure.121.008365_references_DOI_Sr5FmHPrDELw1k8WALkuKcB8xH1"}]}